Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2017

View Archived Issues

Fluvoxamine maleate approved in Japan for pediatric obsessive-compulsive disorder

Taivex initiates phase I study of T-1101 in advanced refractory solid tumors

Spinraza approved in Japan and Canada

Kyowa Hakko Kirin initiates phase III trial of mogamulizumab in HTLV-1 associated myelopathy

Evidence of activity seen with BGB-A317 in hepatocellular carcinoma

FDA accepts for review resubmission of SUN-101/eFlow NDA

PET using [18F]CTT-1057 effectively images prostate cancer

VenatoRx Pharmaceuticals describes novel beta-lactamase inhibitors

Pfizer divulges new GABA(A) receptor modulators

Rice University patents CJ-16264 analogues

Bayer Pharma describes new potassium channel subfamily K member 3/9 blockers

Novel complement factor D inhibitors discovered at Lifesci Pharmaceuticals

New hBUB1 inhibitors synthesized at Bayer Pharma

Onxeo reports preclinical proof-of-concept results for intravenous AsiDNA

TIM-3 and Gal-9 found to impact disease outcome in myelodysplastic syndromes

Saniona acquires NeuroSearch's remaining interest on acquired assets

M Pharmaceutical adds potential pediatric orphan drug to pipeline

New phase II trial explores use of filgotinib in noninfectious uveitis

Amenalief approved in Japan to treat herpes zoster

Zydus initiates phase II trial of ZYAN-1 to treat anemia in chronic kidney disease

Daiichi Sankyo discontinues Japanese development of etanercept biosimilar CHS-0214

Human adipose-derived stromal cells effectively treat experimental glomerulonephritis

Lytix advances phase I trial of LTX-315

Updated phase I/II data for KTE-C19 in pediatric relapsed/refractory acute lymphoblastic leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.